UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):
March 5, 2018

NantHealth, Inc.

(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation) 001-37792 (Commission File Number) 27-3019889 (IRS Employer Identification No.)

9920 Jefferson Blvd Culver City, California 90232 (Address of principal executive offices)(Zip Code)

Registrant's telephone number, including area code: (310) 883-1300

Not Applicable (Former name or former address, if changed since last report)

	ck the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following isions (see General Instruction A.2. below):
	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).	
Eme	rging growth company ⊠
If an	emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or

revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 5.02 – Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On March 5, 2018, Mark Burnett, a member of the Board of Directors ("Board") of NantHealth, Inc. (the "Company"), notified the Company of his desire not to be nominated for reelection as a Board member at the Company's next annual meeting of stockholders due to time constraints and his significant other obligations. Mr. Burnett will continue to serve as a director until the expiration of his term and will have continued involvement in other activities within the NantWorks, LLC family of companies. Mr. Burnett's decision to not stand for re-election to the Board was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

NantHealth, Inc.

By: /s/ Paul Holt

Paul Holt

Chief Financial Officer

Date: March 9, 2018